Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 75.40

+5.5%

4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (53)	9/30/2002 3:17:55 PM
From: Jibacoa	Read Replies (1) of 3722

HEB Is up 27.50% with volume more than 4x its daily average after an analyst upgrade from "speculative buy" to "buy".<g> ( The "target" was also raised from $13.75 to $25. That would be a 2,400% gain from present levels.<G>) "First year revenue after FDA approval for Ampligen's indications in HIV/AIDS and Chronic Fatigue Syndrome (CFS) are projected at $160 million. This is based on a market penetration of only 0.5%, which Mr. Garnet indicates maybe to conservative and consequently revenues could be significantly higher." "The report expresses the belief that Ampligen has more than a 90% probability of obtaining FDA and European regulatory approval for both CFS and HIV/AIDS." "Mr. Garnet has covered the Biotech Industry for over 10 years and has a strong track record for discovering undervalued small cap companies within the industry.".<g> biz.yahoo.com siliconinvestor.com siliconinvestor.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next